RESUMEN
OBJECTIVES: Diabetic nephropathy is a chief reason of mortality particularly in individuals with renal dysfunction. The current research was aimed to assess the nephroprotective portion of Vaccinium oxycoccos toward mice diabetic nephropathy induced by streptozotocin (STZ). V. oxycoccos was purchased and used for hydroalcoholic extraction. METHODS: Sixty male mice were subjected to STZ-intraperitoneal injection (45â¯mg/kg). After diabetes induction, mice were divided into five groups of diabetic control (received only STZ), non-diabetic control (received only citrate buffer), two V. oxycoccos treatment (received V. oxycoccos extract (200 and 400â¯mg/kg) oral daily by gavage), and metformin treatment (received metformin (500â¯mg/kg) oral daily by gavage). Glucose and weight of mice were checked weekly. RESULTS: After 28 days, the effect of V. oxycoccos extract on serum and urine parameters were assessed. STZ caused significant decreased in the mice body weight. Mice treated with the V. oxycoccos (400â¯mg/kg) harbored the lowest weight loss at day 28 (70.2±1.38â¯g). STZ caused significant increase in the mice FBS. Mice treated with the V. oxycoccos (400â¯mg/kg) harbored the lowest FBS at day 28 (189.2±1.20â¯mg/dL). Treatment of mice with V. oxycoccos (400â¯mg/kg) caused the lowest increase in the levels of cholesterol, HbA1c and triglycerides compared to the diabetic control mice. Compared to the diabetic control group, mice treated with V. oxycoccos (400â¯mg/kg) had the highest HDL, insulin, SOD, and GSH (p<0.05). The lowest serum BUN, CR, and UR were found in mice treated with V. oxycoccos (400â¯mg/kg). Anti-inflammatory effects of V. oxycoccos (400â¯mg/kg) was shown by the lowest TNF-α, IL-6, and TGF-ß1 concentration in mice treated with V. oxycoccos (400â¯mg/kg). CONCLUSIONS: The current study disclosed that treatment with V. oxycoccos resulted in substantial development in the serum and urine parameters and also antioxidant and anti-inflammatory response of STZ-induced diabetic mice.
Asunto(s)
Diabetes Mellitus Experimental , Nefropatías Diabéticas , Metformina , Vaccinium macrocarpon , Vaccinium , Ratones , Masculino , Animales , Nefropatías Diabéticas/tratamiento farmacológico , Nefropatías Diabéticas/inducido químicamente , Estreptozocina/efectos adversos , Diabetes Mellitus Experimental/tratamiento farmacológico , Metformina/uso terapéutico , Extractos Vegetales/efectos adversos , Antiinflamatorios/uso terapéutico , GlucemiaRESUMEN
Rheumatoid arthritis (RA) is classified as a persistent inflammatory autoimmune disorder leading to the subsequent erosion of articular cartilage and bone tissue originating from the synovium. The fundamental objective of therapeutic interventions in RA has been the suppression of inflammation. Nevertheless, conventional medicines that lack target specificity may exhibit unpredictable effects on cell metabolism. In recent times, there has been evidence suggesting that specialized pro-resolving mediators (SPMs), which are lipid metabolites, have a role in facilitating the resolution of inflammation and the reestablishment of tissue homeostasis. SPMs are synthesized by immune cells through the enzymatic conversion of omega-3 fatty acids. In the context of RA, there is a possibility of dysregulation in the production of these SPMs. In this review, we delve into the present comprehension of the endogenous functions of SPMs in RA as lipids that exhibit pro-resolutive, protective, and immunoresolvent properties.